Pharmacokinetic profile and in vivo anticancer efficacy of anagrelide administered subcutaneously in rodents

Pharmacokinetic profile and in vivo anticancer efficacy of anagrelide administered subcutaneously in rodents

Anagrelide (ANA) is a phosphodiesterase 3A (PDE3A) inhibitor, commonly prescribed for essential thrombocythemia. It also functions as a molecular glue, inducing complex formation between PDE3A and Schlafen 12. This association either triggers apoptosis or inhibits proliferation in tumor cells, suppo...

Full description

Saved in:
Bibliographic Details
Main Authors: Kirsi Toivanen, Luna De Sutter, Agnieszka Wozniak, Karo Wyns, Nanna Merikoski, Sami Salmikangas, Jianmin Duan, Mikael Maksimow, Maria Lahtinen, Tom Böhling, Patrick Schöffski, Harri Sihto
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Drug Delivery
Subjects:
Anagrelide
subcutaneous
slow-release
pharmacokinetics
GIST
Online Access:https://www.tandfonline.com/doi/10.1080/10717544.2025.2463433
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items